RESEARCH PROFILE
CJC-1295 NO DAC + IPAMORELIN
Dual Pathway Growth Hormone Secretagogue Research
CJC-1295 No DAC and Ipamorelin combine two distinct signaling pathways involved in endogenous growth hormone release. Modified GRF 1-29 acts through the GHRH receptor, while Ipamorelin acts through the ghrelin receptor, creating a complementary approach to studying pulsatile growth hormone signaling.
INVESTIGATIONAL • NOT FDA APPROVED • NO PUBLISHED HUMAN TRIAL OF THE COMBINATION
CJC-1295 NO DAC + IPAMORELIN AT A GLANCE
Category
Growth hormone secretagogue combination
Components
CJC-1295 No DAC • Ipamorelin
Primary Targets
GHRH receptor • Ghrelin receptor / GHSR1a
Primary Research Pathway
Growth hormone • IGF-1 axis
Research Concept
Complementary stimulation of pulsatile GH release
Regulatory Status
Neither component is FDA approved
IMPORTANT DISTINCTION
The two peptides do not activate the same receptor.
CJC-1295 No DAC, commonly called Modified GRF 1-29, acts through the GHRH receptor.
Ipamorelin is a growth hormone secretagogue that acts primarily through the ghrelin receptor, GHSR1a.
The rationale for studying them together is therefore based on complementary signaling rather than simply combining two copies of the same mechanism.
However, the biological rationale for the combination should not be confused with direct clinical evidence. No published human randomized controlled trial has established the safety or efficacy of the CJC-1295 No DAC + Ipamorelin combination.
WHAT IS CJC-1295 NO DAC + IPAMORELIN?
CJC-1295 No DAC + Ipamorelin is a research combination designed to stimulate endogenous growth hormone release through two separate receptor systems.
CJC-1295 No DAC, or Modified GRF 1-29, is a short acting analog of growth hormone releasing hormone.
It acts at the pituitary GHRH receptor, mimicking part of the physiological signal the hypothalamus uses to stimulate growth hormone release.
Ipamorelin belongs to a different class of compounds known as growth hormone secretagogues.
It acts primarily through the ghrelin receptor, also known as the growth hormone secretagogue receptor or GHSR1a.
Because these pathways converge on pituitary growth hormone secretion through different receptor systems, researchers have proposed that simultaneous activation may produce a larger GH pulse than stimulation of either pathway alone.
This concept is commonly described as synergistic or complementary GH secretagogue signaling.
Importantly, the combination itself remains investigational and has not been established as an approved clinical therapy.
MECHANISM OF ACTION
The research rationale for this combination centers on activating two complementary pathways involved in physiological growth hormone release.
CJC-1295 NO DAC — GHRH PATHWAY
CJC-1295 No DAC acts as a GHRH receptor agonist.
GHRH receptor activation at pituitary somatotroph cells stimulates production and release of growth hormone.
Because the No DAC form is short acting, the research concept focuses on relatively brief stimulation rather than the prolonged exposure associated with DAC-containing CJC-1295.
IPAMORELIN — GHRELIN PATHWAY
Ipamorelin acts primarily through the ghrelin receptor, GHSR1a.
Activation of this receptor triggers intracellular signaling that can stimulate growth hormone release from pituitary cells.
This mechanism is distinct from direct GHRH receptor activation.
TWO PATHWAYS, ONE GH RESPONSE
The two receptor systems can interact at the level of the pituitary.
Preclinical cellular research cited in your Project profile indicates that active ghrelin-receptor signaling can potentiate GHRH-mediated signaling in the same cell.
This provides the mechanistic basis for studying a GHRH analog and a ghrelin-receptor agonist together.
DOWNSTREAM IGF-1 SIGNALING
Growth hormone released from the pituitary can subsequently stimulate production of insulin-like growth factor 1, or IGF-1, particularly through hepatic signaling.
IGF-1 therefore serves as one downstream marker commonly examined when studying repeated GH-axis stimulation.
WHY IPAMORELIN?
Ipamorelin was developed as a comparatively selective growth hormone secretagogue.
Research cited in the Project profile reported GH release without significant increases in ACTH or cortisol at studied exposures, distinguishing its pharmacological profile from some older growth hormone secretagogues.
That selectivity is one reason Ipamorelin became a common research pairing with GHRH analogs.
WHAT THE RESEARCH SHOWS
DIRECT COMBINATION EVIDENCE
The most important evidence limitation comes first:
No published human randomized controlled trial has evaluated CJC-1295 No DAC + Ipamorelin as a combined treatment regimen.
The commonly discussed combination is based primarily on:
Mechanistic physiology
Individual compound research
Related CJC-1295 research
Ipamorelin pharmacology
Preclinical receptor research
Community research practices
These sources do not establish clinical efficacy for the combination itself.
CJC-1295 HUMAN RESEARCH
Human research involving longer acting CJC-1295 demonstrated meaningful stimulation of the GH/IGF-1 axis.
Teichman and colleagues reported that CJC-1295 increased growth hormone and IGF-1 concentrations in healthy adults.
The study involved longer acting CJC-1295 rather than the short acting No DAC variant.
It therefore supports the broader biological activity of CJC-1295-related GHRH agonism but does not establish the pharmacokinetics or clinical effects of Modified GRF 1-29.
GROWTH HORMONE PULSATILITY
Research by Ionescu and Frohman reported that pulsatile growth hormone secretion persisted during stimulation with CJC-1295.
This work contributes to understanding how GHRH analog stimulation interacts with endogenous GH pulsatility.
Again, this was not a clinical trial of the CJC-1295 No DAC + Ipamorelin combination.
IPAMORELIN SELECTIVITY
Human and pharmacological research has investigated Ipamorelin independently.
Research cited in your Project profile describes Ipamorelin as a selective growth hormone secretagogue and reports GH stimulation without the same degree of ACTH or cortisol stimulation associated with some older GHRPs.
Human pharmacokinetic and pharmacodynamic research also documented measurable GH responses following Ipamorelin administration.
PRECLINICAL SYNERGY
Cellular research provides a mechanistic rationale for combining the two pathways.
Research cited in your Project source demonstrated that ghrelin receptor signaling can potentiate GHRH receptor signaling within pituitary cells.
This supports the biological plausibility of complementary GH release.
However:
Mechanistic synergy is not the same as demonstrated clinical benefit.
WHAT HAS NOT BEEN ESTABLISHED
Controlled human trials have not established that the CJC-1295 No DAC + Ipamorelin combination produces clinically meaningful improvements in:
Muscle growth
Fat loss
Body composition
Recovery
Sleep quality
Athletic performance
Anti-aging
Longevity
The combination also lacks controlled human evidence establishing an optimal dose, schedule, cycle length, or long-term safety profile.
IMPORTANT EVIDENCE LIMITATION
Evidence from CJC-1295 with DAC, CJC-1295 No DAC, Ipamorelin, GHRH physiology, and ghrelin receptor research should be kept distinct.
The existence of evidence for each pathway does not constitute direct evidence for the combined stack.
SAFETY & RESEARCH CONSIDERATIONS
Because the combination itself lacks controlled human clinical trials, its complete safety profile has not been established.
Safety considerations must therefore draw primarily from the individual compounds and from the physiology of GH-axis stimulation.
COMPOUND LEVEL EFFECTS
Your Project profile identifies commonly discussed effects including:
Facial flushing or warmth
Mild water retention
Injection site irritation
Tingling or numbness
Changes in sleep or vivid dreams
These observations should not be interpreted as a complete adverse-event profile for the combination.
GLUCOSE & INSULIN SENSITIVITY
Growth hormone is counter-regulatory to insulin and can influence glucose metabolism.
Repeated GH-axis stimulation may therefore be relevant to:
Fasting glucose
Insulin sensitivity
A1c
Existing diabetes or prediabetes
The Project profile specifically identifies glucose monitoring as an important consideration.
FLUID RETENTION
GH-axis stimulation can contribute to fluid retention.
Persistent edema, substantial swelling, or symptoms accompanied by shortness of breath or cardiovascular symptoms warrant medical evaluation rather than being assumed to be a routine peptide effect.
IGF-1 & CELL GROWTH
Repeated GH stimulation can increase downstream IGF-1 signaling.
Because GH and IGF-1 participate in cellular proliferation and growth pathways, your Project source identifies active cancer, prior cancer history, or unexplained tumors as important concerns requiring clinical consideration.
This is a biological precaution and does not establish that the combination causes cancer.
CARPAL TUNNEL TYPE SYMPTOMS
Tingling or numbness in the hands can occur in the context of excessive GH/IGF-1 exposure and fluid retention.
Persistent neurological symptoms warrant appropriate medical assessment.
LONG TERM UNCERTAINTY
There are no robust long-term human safety data for the CJC-1295 No DAC + Ipamorelin combination.
The absence of demonstrated ACTH or cortisol elevation with Ipamorelin in certain studies also does not establish the overall combination as risk free.
REGULATORY CONTEXT
THE COMBINATION IS NOT FDA APPROVED
Neither CJC-1295 No DAC nor Ipamorelin is FDA approved for clinical use.
There is no FDA approved CJC-1295 No DAC + Ipamorelin combination drug.
FDA COMPOUNDING REVIEW
Your Project profile documents FDA regulatory review involving both CJC-1295-related substances and Ipamorelin.
It notes that FDA has raised concerns involving proposed compounded uses of these substances, including questions surrounding characterization, safety, immunogenicity, and available clinical evidence.
The Project source also notes that the federal compounding landscape has changed over time and should be checked against current FDA and Federal Register information before making specific compounding claims.
RESEARCH AVAILABILITY IS NOT APPROVAL
The fact that these compounds are available through research suppliers does not establish:
FDA approval
Clinical effectiveness
Medical suitability
Manufacturing consistency
Sterility
Purity
An approved human dosing regimen
RELATED GH COMPOUNDS ARE NOT INTERCHANGEABLE
CJC-1295 No DAC + Ipamorelin should not be treated as equivalent to:
CJC-1295 with DAC
Sermorelin
Tesamorelin
Recombinant human growth hormone
GHRP-2 or GHRP-6
Each differs in receptor pharmacology, duration of action, evidence base, regulatory status, or safety profile.
Research status matters. Mechanistic rationale and individual-compound evidence do not constitute regulatory approval or clinical validation of the combination.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
CJC-1295 NO DAC / IPAMORELIN 5 MG / 5 MG
Laboratory
Optiq Health Labs
Sample Name
cjc 1295 ipamorelin
Sample ID
1275.OPT.260910
Lot
ld07292026-3
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Report Date
September 18, 2026
Reported Net Content
CJC-1295: 4.96 mg/vial
Ipamorelin: 4.87 mg/vial
Total reported peptide content: 9.83 mg/vial
Reported Purity
99.3% • RP-HPLC
Identity
CJC-1295 + Ipamorelin
LC-MS Confirmation • Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth
IMPORTANT PRODUCT MATCHING NOTE
This analytical report is specifically for the sample identified as “cjc 1295 ipamorelin”, lot ld07292026-3, with reported contents of 4.96 mg CJC-1295 and 4.87 mg Ipamorelin per vial.
These findings are consistent with a nominal 5 mg / 5 mg blend, totaling approximately 10 mg per vial.
This report should not be represented as analytical verification of a 10 mg / 10 mg blend, which would contain a nominal total of 20 mg per vial.
The laboratory identifies the tested compounds as CJC-1295 + Ipamorelin. The report does not explicitly state “no DAC”; therefore, the no-DAC designation should be confirmed through separate product identity documentation.
Croix requires the physical product, labeled strength, and lot to match the laboratory report before representing the COA as supporting that product.
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Teichman SL, Neale A, Lawrence B, et al.
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GHRH.
Journal of Clinical Endocrinology & Metabolism. 2006.
Human research examining GH and IGF-1 responses to longer acting CJC-1295.
Ionescu M, Frohman LA.
Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog.
Journal of Clinical Endocrinology & Metabolism. 2006.
Human research examining GH pulsatility during CJC-1295 stimulation.
Alba M, Fintini D, Sagazio A, et al.
Research examining CJC-1295 in a GHRH-knockout animal model.
Preclinical evidence relevant to GHRH receptor signaling.
Raun K, Hansen BS, Johansen NL, et al.
Ipamorelin, the first selective growth hormone secretagogue.
European Journal of Endocrinology. 1998.
Pharmacological research characterizing Ipamorelin's growth hormone secretagogue activity and selectivity.
Gobburú JV, Agersø H, Jusko WJ, Ynddal L.
Pharmacokinetic and pharmacodynamic modeling of Ipamorelin in healthy volunteers.
Human evidence characterizing Ipamorelin pharmacology and GH response.
Cunha SR, Mayo KE.
Research demonstrating interaction between ghrelin receptor and GHRH receptor signaling in pituitary cells.
Mechanistic evidence supporting the biological rationale for complementary GHRH and ghrelin receptor stimulation.
EVIDENCE NOTE
These references evaluate the individual compounds, related CJC-1295 formulations, or underlying receptor biology.
They should not be cited as though they constitute a clinical trial of the CJC-1295 No DAC + Ipamorelin combination.
No published human randomized controlled trial of this specific combination is identified in the current Project source.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish CJC-1295 No DAC + Ipamorelin as safe or effective for personal use.
CJC-1295 No DAC and Ipamorelin are not FDA approved, and the combination itself does not have an FDA approved therapeutic indication.
Although the two compounds act through complementary receptor pathways involved in endogenous growth hormone release, mechanistic synergy should not be interpreted as demonstrated clinical benefit.
No published human randomized controlled trial has established the safety or efficacy of the CJC-1295 No DAC + Ipamorelin combination for muscle growth, fat loss, body composition, recovery, sleep, anti-aging, longevity, or other commonly discussed outcomes.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.